WillItSurvive
Pharma and healthcare groups · United States

Eli Lilly

lilly.com ↗

Eli Lilly is a pharma giant whose obesity drug tirzepatide now drives most of its revenue.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from August 5-6, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report
The call

Lilly's fortunes now ride almost entirely on one drug family, with Novo Nordisk's pill and U.S. price rules as the main things that could shake that.

Eli Lilly makes Mounjaro and Zepbound, injectable drugs that help people lose weight and manage diabetes, and these two medicines bring in about two-thirds of the company's total sales. The company is hard to copy right now because it has patent protection for several more years, a direct sales team and relationships with pharmacy insurance companies that took years to build, and manufacturing plants competitors cannot quickly set up. Novo Nordisk has already released a pill version of a similar drug in Europe and the UK, and the U.S. government is pushing prices down hard, which means Eli Lilly's profits could shrink even if sales stay strong, or the single drug losing some of its power if someone proves it causes unexpected health problems.

Why
01
AI pressure: AI-driven drug discovery labs like Isomorphic Labs and Xaira Therapeutics. AI speeds up molecule design for rivals chasing obesity drugs, but it cannot skip clinical trials or FDA review. Could AI do the core job? Unlikely.
02
Bigger players: Novo Nordisk. Novo's oral GLP-1 pill already has EU and UK approval, landing before Lilly's own oral candidate, Foundayo. Could a giant copy it? No, they are blocked.
03
What protects it. Patents on tirzepatide, FDA approval barriers, and manufacturing capacity that took years to build.
What would change this call
Lilly's Foundayo (oral tirzepatide) approval and launch timing versus Novo's oral Wegovy rollout. shows whether Lilly keeps first-mover ground or cedes oral GLP-1 share to Novo Nordisk.
Q2 2026 earnings (Aug 5-6) tirzepatide revenue growth rate versus prior 80-125% YoY pace. reveals if the core Mounjaro/Zepbound franchise growth is slowing under pricing pressure or competition.
Outcome of TrumpRx and Medicare GLP-1 Bridge pricing programs on Lilly's realized US drug prices. shows how much government pricing compression is eating into tirzepatide margins.
Key numbers
  • FY2025 revenue $65.18B, up 44.7% YoY (2025-12-31)
  • Tirzepatide made up 65% of Q1 2026 revenue (2026-03-31)
  • First healthcare firm to hit $1 trillion market cap (2025-11-30)
Named risks
  • Tirzepatide franchise concentration at ~65% of revenue creates binary exposure to any safety or efficacy setback. Severity: high
  • Active product-liability litigation (McMurdy, Williams, Baker, Ante cases filed March-June 2026). Severity: medium
  • US government pricing programs like TrumpRx and Medicare GLP-1 Bridge flagged as low-to-mid-teens drag on 2026 guidance. Severity: medium
  • Novo Nordisk and Pfizer oral GLP-1 and injectable competitors could erode share in the obesity market. Severity: medium
  • AtaiBeckley acquisition pending regulatory and stockholder approval, could face delay or antitrust scrutiny. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Novo NordiskcontestingNovo's Wegovy oral pill got EU/UK approval around the same window as Lilly's Foundayo, April 2026
Pfizergaining onPfizer targeting obesity drug approval around 2028 via Metsera acquisition, per June 2026 reports
Rochegaining onRoche developing CT-388 and amylin obesity candidates via Carmot Therapeutics acquisition, 2026
Mercklosing toMounjaro Q1 2026 sales of $8.7B surpassed Keytruda's $7.9B, May 2026
AstraZeneca, Amgen, Boehringer IngelheimcontestingPresenting competing obesity and metabolic drug data through 2026
Questions people ask
Is Eli Lilly profitable in 2026?
Yes. Lilly posted Q1 2026 revenue of $19.8 billion, up 55-56% YoY, with non-GAAP EPS of $8.55, and raised FY2026 guidance to $82-85 billion revenue as of July 2026, driven mainly by tirzepatide sales growth.
What is Eli Lilly's biggest competitor?
Novo Nordisk is Lilly's primary rival in the GLP-1/obesity market. Novo's Wegovy oral pill gained EU/UK approval around the same time as Lilly's Foundayo pill launched in the US on April 1, 2026, intensifying direct competition for the same patients.
Could AI replace Eli Lilly's drug discovery process?
AI is reshaping early discovery via partners like Insilico Medicine ($2.75B deal, March 2026) and NVIDIA's Blackwell GPU supercomputer, but Lilly retains exclusive manufacturing, FDA approval and liability control, meaning AI augments rather than replaces the regulated core business as of mid-2026.
Is Eli Lilly a safe company to work for right now?
Headcount grew to 50,000 employees as of December 31, 2025, up from 47,000 in 2024, with job postings up 45.4% YoY, suggesting active hiring rather than layoffs, though litigation and pricing pressure remain risks to monitor.
How much of Eli Lilly's revenue comes from Mounjaro and Zepbound?
Tirzepatide (Mounjaro and Zepbound combined) generated about $12.8-12.9 billion in Q1 2026 alone, roughly 65% of total company revenue, and $36.5 billion of Lilly's $65.18 billion FY2025 revenue.
Who owns Eli Lilly?
Eli Lilly is publicly traded on the NYSE under LLY with no parent company. The Lilly Endowment, a charitable foundation created in 1937 by the founding family, owns 9.8% of shares, while institutional investors hold about 89% as of July 2026.
Timeline
  • 2026-07-16Lilly announces AtaiBeckley acquisition for up to $3.8B, its eighth deal of the year, near $26B cumulative
  • 2026-04-01FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill, via priority voucher program
  • 2026-03-31Q1 2026 revenue hits $19.8B, up 55-56% YoY; Mounjaro revenue reaches $8.7B
  • 2026-03-29Insilico Medicine AI drug discovery deal expanded to up to $2.75B
  • 2026-01-12NVIDIA and Lilly announce Co-Innovation AI Lab, up to $1B over 5 years
  • 2025-11-30Lilly becomes first healthcare company to reach $1 trillion market capitalization
  • 2025-10-28Lilly deploys AI supercomputer with 1,000+ NVIDIA Blackwell B300 GPUs
  • 2025-09-11Lilly pauses a potential UK manufacturing investment citing pricing concerns
Head to head
Eli Lilly vs Telix Pharmaceuticals
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources